Skip to main
GYRE

GYRE Stock Forecast & Price Target

GYRE Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gyre Therapeutics Inc. demonstrates a strong financial outlook due to its strategic acquisition of generic nintedanib, which enhances its position in the idiopathic pulmonary fibrosis (IPF) market and provides essential capital for its operations. This acquisition not only reinforces Gyre's leadership in developing therapies targeting both lung and liver fibrosis but also aligns with its commitment to diversifying its product offerings, particularly through commercial-stage products like ETUARY, Avatrombopag, and ongoing developments such as Hydronidone for MASH fibrosis. With a robust pipeline including drug candidates in China, Gyre's capabilities in addressing organ diseases further support its potential for sustained revenue growth during challenging market conditions.

Bears say

Gyre Therapeutics Inc faces significant challenges due to depressed forward multiples, attributed to current market volatility, which diminishes investor confidence. The company's reliance on commercial sales of pirfenidone in China presents a further concern, as this asset is not expected to generate substantial revenue growth, indicating a plateau in earnings potential. Additionally, the uncertainty regarding cash burn, influenced by the developmental stages of various programs and potential offsetting revenues from collaborations, adds to the financial risks associated with the company’s operational outlook.

GYRE has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gyre Therapeutics Inc (GYRE) Forecast

Analysts have given GYRE a Strong Buy based on their latest research and market trends.

According to 2 analysts, GYRE has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gyre Therapeutics Inc (GYRE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.